1
EXHIBIT 10.50
MEMORANDUM
This memorandum made and effective as of this 9th day of February, 2000 by and
between
NIPPON KAYAKU CO., LTD. ("NKC")
and
SIGNAL PHARMACEUTICALS INC. ("SIGNAL"),
WITNESSETH THAT:
WHEREAS, NKC and SIGNAL concluded a collaboration agreement as of February 9,
1998 ("Collaboration Agreement"); and
WHEREAS, NKC and SIGNAL desire to establish a collaborative relationship to
develop and commercialize novel drug products based on or derived from compounds
identified under Collaboration Agreement for the treatment and prevention of
diseases and disorders of the peripheral nervous system and central nervous
system; and
WHEREAS, SIGNAL has made a draft of Joint Development and Commercialization
Agreement ("Joint Agreement") and sent it to NKC and NKC sent a revised draft
dated January 31, 2000 to SIGNAL; and
WHEREAS, NKC and SIGNAL have intent to conclude Joint Agreement and are
negotiating with each other on the revised draft in good faith;
NOW THEREFORE, the parties hereto agree as follows:
1. Notwithstanding the provisions of Collaboration Agreement, the parties hereto
shall conclude Joint Agreement by the end of March 2000 and the effective date
of Joint Agreement shall be February 9, 2000.
2. In order to expedite the research and development under Joint Agreement, the
parties hereto shall carry out the following activities prior to and until
conclusion of Joint Agreement.
1
2
(1) Each party's representative of RMC shall agree to and sign a
protocol for studies on which the both parties hereto shall bear costs and
expenses jointly.
(2) Both of the parties hereto shall sign agreements with contract
laboratories for entrusting studies.
(3) The parties hereto deal costs and expenses according to the method
as before pursuant to Collaboration Agreement.
(4) The parties hereto determine long-range, annual and quarterly
research and development plans until the start of commercialization as well as
budgets and personnel plans in accordance with such research and development
plans.
(5) The parties hereto shall determine research and development plans,
budgets and personnel plans on research related to additional indications and
research of succeeding compounds.
IN WITNESS WHEREOF, the parties hereto have caused this memorandum in
English language to be executed in duplicate by their respective duly authorized
representatives.
NIPPON KAYAKU CO., LTD.
/s/ Xxxxxx Xxxxxx
----------------------------------------
Xxxxxx XXXXXX
General Manager
Intellectual Property Division
Date: February 9, 2000
SIGNAL PHARMACEUTICALS INC.
/s/ Xxxx X. Xxxxx
----------------------------------------
Xxxx X. XXXXX
President and Chief Executive Officer
Date: February 9, 2000
2
